ACADIA Pharmaceuticals reported strong revenue growth driven by its commercial products, NUPLAZID and DAYBUE, alongside disciplined management of operating expenses. The company continues to invest in its late-stage clinical pipeline while showing significant progress toward sustained profitability.
Acadia delivered strong Q3 results with 22% revenue growth, raised DAYBUE guidance, and optimized its Phase 3 ADP program despite a Phase 2 primary endpoint miss, supported by a $976 million cash position.
Acadia Pharmaceuticals reported Q3 2026 total revenues of $342 million, a 22% increase year-over-year, driven by strong sales of DAYBUE and NUPLAZID. The company raised its 2026 net sales guidance for DAYBUE to $505–$520 million and highlighted upcoming Phase 2 readouts for its pipeline candidates in 2027.
Term
Q3 2026
“Acadia delivered a strong third quarter, with total revenues of $342 million and continued commercial momentum across DAYBUE and NUPLAZID. In the U.S., DAYBUE delivered another strong quarter, supported by meaningful uptake of DAYBUE STIX. In Europe, we are excited to build momentum following our recent launch of DAYBU in Germany. NUPLAZID also performed well, driven by underlying demand and the continued expansion of our commercial reach.”
Catherine Owen Adams, Chief Executive Officer of Acadia
Acadia Pharmaceuticals EVP, CFO Mark C. Schneyer Sells $69.3K of Stock
Mark C. Schneyer, EVP, CFO, sold 3,321 shares of Acadia Pharmaceuticals Inc at $20.88 a share, worth $69.3K in total on Oct 30, 2026. Shares held after the trade: 71,322 (-4.4%).
Elizabeth H.Z. Thompson, Ph.D., has stepped down from her role as Executive Vice President and Head of Research and Development at Acadia Pharmaceuticals effective October 23, 2026. Dr. Thompson will transition to a consulting role through December 31, 2026, while the company continues its search for a permanent replacement.